MIRA Pharmaceuticals submitted the Phase 2a protocol for Ketamir-2 to IRB after FDA review, targeting site initiation in Q1 2027 to evaluate efficacy in chemotherapy-induced peripheral neuropathy.
MIRA Pharmaceuticals submitted the Phase 2a protocol for Ketamir-2 to IRB after FDA review, targeting site initiation in Q1 2027 to evaluate efficacy in chemotherapy-induced peripheral neuropathy.